BioSpace

We’re investigating how many hours full-time biopharma professionals work each week, on average. Please vote in the poll below, and feel free to share your thoughts in the comments.

Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance. #pharma #research #biospace https://hubs.li/Q03dGBW60

The announcement by the Department of Health and Human Services highlighted a flurry of moves, which include the shifting of departments. Also this week, HHS Secretary Robert F. Kennedy Jr. tapped fellow vaccine critic David Geier to investigate vaccine safety within the CDC. #HHS #CDC #policy #biospace https://hubs.li/Q03dGBgF0

Nkarta, Inc., ElevateBio and Atea Pharmaceuticals, Inc have joined the growing list of biopharma companies cutting their workforce this month. Get the details in our regularly updated layoff tracker. #layoffs #biopharma #biospace https://hubs.li/Q03dGfBx0

Looking for a biopharma job in Indiana? Check out our list of seven companies hiring life sciences professionals like you. #nowhiring #biopharma #biospace https://hubs.li/Q03dFZwm0

Last month, Deerfield Management accused Alcon of obstructing Aurion’s IPO plans so it could acquire the startup “at a discount.” #acquisition #pharma #biospace https://hubs.li/Q03dFcXp0

Biopharma employees reporting a positive business outlook for their companies dropped month over month but increased year over year in February, according to the Glassdoor Employee Confidence Index. Glassdoor’s findings align with recent BioSpace data. #employeesentiment #biopharma #biospace https://hubs.li/Q03dG6BK0

Soleno’s Vykat XR is the first drug approved for the rare disease that directly targets its hallmark symptom. #FDA #biospace https://hubs.li/Q03dFcv90

In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses the evolution of women’s inclusion in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine. #podcast #DIA #inclusion #clinicaltrials #biospace https://hubs.li/Q03dFTRj0

The latest data from Johnson & Johnson’s Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso on overall survival. But analysts say the next step is getting a subcutaneous formula approved. #lungcancer #pharma #biospace https://hubs.li/Q03dFcVl0